From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

Delaying diagnosis of parkinsonism can mean delaying care. In a study recently published in JAMA Neurology, David Vaillancourt, PhD, and colleagues tested the ability of an AI model to differentiate between Parkinson disease and other neurodegenerative disorders when paired with MRI. He joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH to discuss. Related Content: A Large Proportion of Parkinson Disease Diagnoses Are Wrong—Here’s How AI Could Help Automated Imaging Differentiation for Parkinsonism

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia

Interview with Sameer Jauhar, PhD, author of Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD. Related Content: Incidence and Nature of Antidepressant Discontinuation Symptoms

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

Nationwide data are unavailable regarding changes in intensive care unit (ICU) outcomes over the past 10 years, limiting understanding of practice changes. Authors Emily Moin, MD, MBE, and Scott D. Halpern, MD, PhD, MBE, of the University of Pennsylvania join JAMA Associate Editor Christopher W. Seymour, MD, MSc, to discuss how ICU care and outcomes have changed in the US over the past decade. Related Content: Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units

The incidence of invasive group A streptococcal infections has risen in the US. Similar observations have been reported in other parts of the world. Authors Joshua Osowicki, MBBS, PhD, of Murdoch Children’s Research Institute and Theresa L. Lamagni, MSc, PhD, of the United Kingdom Health Security Agency join JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss the public health challenge posed by group A strep. Related Content: Invasive Group A Streptococcal Disease in the US Invasive Group A Streptococcal Infections in 10 US States

Less than 20% of patients eligible for lung cancer screening get screened in the US. A recent study examined whether adults eligible for lung cancer screening engage in screening for other types of cancer. Coauthor Chi-Fu Jeffrey Yang, MD, of Harvard Medical School joins JAMA Deputy Editor Tracy Lieu, MD, to discuss. Related Content: Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US

Despite increased participation in US long-distance running races, cardiac arrest incidence remains stable. Authors Jonathan Kim, MD, MSc, of Emory University, and Aaron Baggish, MD, of the University of Lausanne Switzerland, discuss the RACER 2 study and compare results with initial findings published in the RACER 1 study from 13 years ago, with JAMA Associate Editor Gregory Marcus, MD, MAS. Related Content: Cardiac Arrest During Long-Distance Running Races

ARDS, which is characterized by hypoxemic respiratory failure and inflammatory injury to the lungs, has a mortality rate of 30% to 40%. Balasubramanian Venkatesh, MD, of the George Institute for Global Health joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the effects of inhaled sedation with sevoflurane for patients with moderate to severe ARDS. Related Content: Sevoflurane Sedation in Acute Respiratory Distress Syndrome Inhaled Sedation in Acute Respiratory Distress Syndrome

The US Food and Drug Administration (FDA) issued new draft regulatory guidance for pulse oximeters related to skin pigment. The guidance is a step forward but it may have unintended consequences. Authors Michael Lipnick, MD, and Philip Bicker, MD, PhD, professors of anesthesia at University of California, San Francisco, discuss this and more with JAMA Executive Editor Gregory Curfman, MD. Related Content: Pulse Oximetry and Skin Pigmentation—New Guidance From the FDA Adherence to FDA Guidance on Pulse Oximetry Testing Among Diverse Individuals, 1996-2024 Addressing Racial and Ethnic Bias in Pulse Oximeters—A Wicked Problem Evaluating the Accuracy of Pulse Oximetry in Children According to Race